IGC

0.2749

1.81% 0.0049

Dopo l'orario di chiusura: .27 -0.0049 -1.78%

IGC Pharma Inc (IGC)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Forum Previsione Frazionamento azionario

Precedente Chiudi:

$0.27

Aprire:

$0.279

Volume 24 ore:

629.70K

Relative Volume:

0.97

Capitalizzazione di mercato:

$28.42M

Reddito:

$1.27M

Utile/perdita netta:

$-7.12M

Rapporto P/E:

-5.2663

EPS:

-0.0522

Flusso di cassa netto:

$-5.28M

1 W Prestazione:

-2.66%

1M Prestazione:

-7.10%

6M Prestazione:

+3.70%

1 anno Prestazione:

-31.96%

Intervallo 1D:

$0.2694

$0.279

Intervallo di 1 settimana:

$0.2665

$0.298

Portata 52W:

$0.235

$0.4508

IGC Pharma Inc Stock (IGC) Company Profile

Nome

IGC Pharma Inc

Settore

Healthcare (1064)

Industria

Biotechnology (595)

Telefono

301-983-0998

Indirizzo

4336 Montgomery Avenue, Bethesda, MD

Dipendente

Cinguettio

@IGCIR

Prossima data di guadagno

2026-11-13

Ultimi documenti SEC

IGC's Discussions on Twitter

Compare IGC vs VRTX, MRNA, REGN, ARGX, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
IGC IGC Pharma Inc	0.2749	29.20M	1.27M	-7.12M	-5.28M	-0.0522
VRTX Vertex Pharmaceuticals Inc	504.73	133.37B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	190.01	79.40B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	735.20	81.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	919.21	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	206.64	43.93B	742.00K	-1.37B	-1.07B	-7.0731

IGC Pharma Inc Borsa (IGC) Ultime notizie

Oct 01, 2026

Press Releases about Ping An Biomedical Co., Ltd.Class A Ordinary Shares (Nasdaq:PASW) - FinancialContent

Oct 01, 2026

Sep 30, 2026

IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026 - BioBuzz

Sep 30, 2026

Sep 29, 2026

Each of two children received 100,000 shares as gifts from IGC Pharma (IGC) CEO Ram Mukunda. - Stock Titan

Sep 29, 2026

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock. Raising P/T to $4.50." - ACCESS Newswire

Sep 29, 2026

Sep 28, 2026

2026 Nanocap Stocks to Watch: IGC, KNRX, GYGY, ARAY Lead Watchlist Now See More Inside! - openPR.com

Sep 28, 2026

IGC Pharma Completes Enrollment in CALMA Phase 2 Trial for Alzhe - GuruFocus

Sep 28, 2026

168 people are enrolled in a trial for Alzheimer's-related agitation. Results are expected in 2026's final quarter. - Stock Titan

Sep 28, 2026

Sep 15, 2026

PullBack Stocks PDSB, PRSO, IGC, RETO: Who Breaks First? - openPR.com

Sep 15, 2026

Sep 14, 2026

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75." - ACCESS Newswire

Sep 14, 2026

Sep 12, 2026

IGC Pharma Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs

Sep 12, 2026

Sep 10, 2026

IGC Q1 2026 Earnings: Narrower-Than-Expected Loss as Clinical-Stage Pipeline Stays in FocusWeak Earnings Momentum - careplusvn.com

Sep 10, 2026

Sep 09, 2026

IGC Pharma Evaluates Recovery After Left Verdict - ACCESS Newswire

Sep 09, 2026

Sep 07, 2026

Price to earnings forward of IGC Pharma, Inc. – AMEX:IGC - TradingView

Sep 07, 2026

Sep 01, 2026

IGC Pharma (NYSE: IGC) Target Raised on Alzheimer's 2027 Outlook - marketscreener.com

Sep 01, 2026

Aug 31, 2026

IGC Pharma (IGC) Slips to $0.31 as Key Support Comes into FocusMerger Arbitrage - dars.gov.et

Aug 31, 2026

Aug 27, 2026

Nasdaq 30's VIVS, IGC, RIME, AIXI Stocks Now - openPR.com

Aug 27, 2026

Aug 26, 2026

Nasdaq 30’s VIVS, IGC, RIME, AIXI Stocks Now - FinancialContent

Aug 26, 2026

IGC Q1 2026 Earnings: Narrower Loss Beats Estimates as Pipeline Progress Supports SentimentMargin Improvement Report - careplusvn.com

Aug 26, 2026

Aug 24, 2026

IGC (IGC) Technicals: Falls 0.65% to $0.31 on the Day; Level Watch: $0.29 and $0.33 Define the Nearby Reference Levels in the Latest ReadingLarge Cap Trends - vinanet.vn

Aug 24, 2026

Aug 20, 2026

MicroCaps IGC, BIVI, ORBS, RIME Sub-$1 Stocks to Watch Now - openPR.com

Aug 20, 2026

Aug 18, 2026

IGC Pharma earnings matched, revenue fell short of estimates By Investing.com - Investing.com India

Aug 18, 2026

IGC (IGC) Earnings Data Review: The Bottom-Line Figure Outpaces Its Comparison at the Close; Session Reaction: Shares Move 1.43% Higher in the Current UpdatePost-Earnings Reaction - vinanet.vn

Aug 18, 2026

IGC Pharma earnings matched, revenue fell short of estimates - Investing.com

Aug 18, 2026

Aug 17, 2026

IGC Pharma Releases Q2 2026 Financial Results - AlphaStreet

Aug 17, 2026

VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum - openPR.com

Aug 17, 2026

IGC Pharma execs buy 4.27M shares to settle $1.15M debt - scanx.trade

Aug 17, 2026

IGC Pharma Q2 Results: Sales up 39% YoY, EPS loss widens to $(0.03) - scanx.trade

Aug 17, 2026

IGC Looks 24.1% Overvalued on GF Value™ - GuruFocus

Aug 17, 2026

IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure - Finviz

Aug 17, 2026

IGC Pharma Q2 Results: CALMA Nears Enrollment Closure - accessnewswire.com

Aug 17, 2026

Aug 14, 2026

IGC Pharma, Inc. 2026: Revenue $265K, EPS ($0.03) — 10-Q Summary - TradingView

Aug 14, 2026

IGC Pharma (NYSE: IGC) widens loss while Phase 2 Alzheimer’s trial hits key milestone - Stock Titan

Aug 14, 2026

IGC Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 14, 2026

Microcaps TOON, IGC, SURG, MDXH to Watch Now as Earnings, AI and Biotech Catalysts Build - openPR.com

Aug 14, 2026

Aug 13, 2026

IGC Pharma (NYSE American:IGC): What Does the Latest Update Mean for Clinical Development? - Kalkine Media

Aug 13, 2026